STOK
Stoke Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$2.06B
P/E Ratio
—
EPS
$-0.12
Beta
1.22
52W High
$40.22
52W Low
$6.42
50-Day MA
$33.21
200-Day MA
$26.06
Dividend Yield
—
Profit Margin
-3.73%
Forward P/E
204.08
PEG Ratio
—
About Stoke Therapeutics Inc
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops new antisense oligonucleotide (ASO) drugs to treat the underlying causes of serious genetic diseases in the United States. The company is headquartered in Bedford, Massachusetts.
Fundamentals
| Revenue (TTM) | $184.42M |
| Gross Profit (TTM) | $184.42M |
| EBITDA | $-18.82M |
| Operating Margin | -4382.00% |
| Return on Equity | -2.37% |
| Return on Assets | -3.73% |
| Revenue/Share (TTM) | $3.11 |
| Book Value | $5.98 |
| Price-to-Book | 5.49 |
| Price-to-Sales (TTM) | 11.18 |
| EV/Revenue | 8.97 |
| EV/EBITDA | 52.48 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -93.80% |
| Shares Outstanding | $59.15M |
| Float | $43.83M |
| % Insiders | 4.10% |
| % Institutions | 119.12% |
Historical Volatility
HV 10-Day
43.84%
HV 20-Day
61.64%
HV 30-Day
61.41%
HV 60-Day
65.15%
HV Rank
25.0%
Volatility is currently contracting
Analyst Ratings
Consensus ($45.10 target)
1
Strong Buy11
BuyData last updated: 4/9/2026